Profile of ipilimumab and its role in the treatment of metastatic melanoma

References

• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
   PubMed Web of Science ®Google Scholar
• SmithFODowneySGKlapperJATreatment of metastatic melanoma using interleukin-2 alone or in conjunction with vaccinesClin Cancer Res200814175610561818765555
   PubMed Web of Science ®Google Scholar
• DudleyMEYangJCSherryRAdoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensJ Clin Oncol200826325233523918809613
   PubMed Web of Science ®Google Scholar
• BesserMJShapira-FrommerRTrevesAJClinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patientsClin Cancer Res20101692646265520406835
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangJCSherryRMDurable complete responses in heavily pretreated patients with metastatic melanoma Using T cell transfer immunotherapyClin Cancer Res201117134550455721498393
   PubMed Web of Science ®Google Scholar
• SznolMPowderlyJDSmithDCSafety and antitumor activity of biweekly MDX-1106 (Anti-PD-1, BMS-936558/ONO-4538) in patients with advanced refractory malignancies [abstract]J Clin Oncol20102815s2506
   Web of Science ®Google Scholar
• WeberJImmune checkpoint proteins: a new therapeutic paradigm for cancer – preclinical background: CTLA-4 and PD-1 blockadeSemin Oncol201037543043921074057
   PubMed Web of Science ®Google Scholar
• CurranMAMontalvoWYagitaHAllisonJPPD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumorsProc Natl Acad Sci U S A201010794275428020160101
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010363871172320525992
   PubMed Web of Science ®Google Scholar
• LeeKMChuangEGriffinMMolecular basis of T cell inactivation by CTLA-4Science19982825397226322669856951
   PubMed Web of Science ®Google Scholar
• EgenJGKuhnsMSAllisonJPCTLA-4: new insights into its biological function and use in tumor immunotherapyNat Immunol20023761161812087419
   PubMed Web of Science ®Google Scholar
• TivolEABorrielloFSchweitzerANLynchWPBluestoneJASharpeAHLoss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4Immunity1995355415477584144
   PubMed Web of Science ®Google Scholar
• WaterhousePPenningerJMTimmsELymphoproliferative disorders with early lethality in mice deficient in Ctla-4Science199527052389859887481803
   PubMed Web of Science ®Google Scholar
• ChambersCASullivanTJAllisonJPLymphoproliferation in CTLA-4-deficient mice is mediated by costimulation-dependent activation of CD4+ T cellsImmunity1997768858959430233
   PubMed Web of Science ®Google Scholar
• KelerTHalkEVitaleLActivity and safety of CTLA-4 blockade combined with vaccines in cynomolgus macaquesJ Immunol2003171116251625914634142
   PubMed Web of Science ®Google Scholar
• MorseMATechnology evaluation: ipilimumab, Medarex/Bristol-Myers SquibbCurr Opin Mol Ther20057658859716370382
   PubMedGoogle Scholar
• PalmisanoGLTazzariPLCozziEExpression of CTLA-4 in nonhuman primate lymphocytes and its use as a potential target for specific immunotoxin-mediated apoptosis: results of in vitro studiesClin Exp Immunol2004135225926614738454
   PubMed Web of Science ®Google Scholar
• Anonymous (Study No. DS06064: BMS-663513 and BMS-734016 (MDX-010): One-month Intravenous Combination Toxicity Study in MonkeysBristol-Myers Squibb Company2007
   Google Scholar
• KohnDBDottiGBrentjensRCARs on track in the clinicMol Ther201119343243821358705
   PubMed Web of Science ®Google Scholar
• SandersonKScotlandRLeePAutoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanomaJ Clin Oncol200523474175015613700
   PubMed Web of Science ®Google Scholar
• MakerAVPhanGQAttiaPTumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin 2: a phase I/II studyAnn Surg Oncol200512121005101616283570
   PubMed Web of Science ®Google Scholar
• PhanGQYangJCSherryRMCancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanomaProc Natl Acad Sci U S A2003100148372837712826605
   PubMed Web of Science ®Google Scholar
• AttiaPPhanGQMakerAVAutoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4J Clin Oncol200523256043605316087944
   PubMed Web of Science ®Google Scholar
• WeberJSO’DaySUrbaWPhase I/II study of ipilimumab for patients with metastatic melanomaJ Clin Oncol200826365950595619018089
   PubMed Web of Science ®Google Scholar
• MakerAVYangJCSherryRMIntrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanomaJ Immunother200629445546316799341
   PubMed Web of Science ®Google Scholar
• WolchokJDNeynsBLinetteGIpilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging studyLancet Oncol201011215516420004617
   PubMed Web of Science ®Google Scholar
• HershEMO’DaySJPowderlyJA phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naive patients with advanced melanomaInvest New Drugs201129348949820082117
   PubMed Web of Science ®Google Scholar
• O’DaySJMaioMChiaron-SileniVEfficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II studyAnn Oncol20102181712171720147741
   PubMed Web of Science ®Google Scholar
• WeberJThompsonJAHamidOA randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanomaClin Cancer Res200915175591559819671877
   PubMed Web of Science ®Google Scholar
• ParkhurstMRSalgallerMLSouthwoodSImproved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residuesJ Immunol19961576253925488805655
   PubMed Web of Science ®Google Scholar
• KawakamiYRobbinsPFWangXIdentification of new melanoma epitopes on melanosomal proteins recognized by tumor infiltrating T lymphocytes restricted by HLA-A1, -A2, and -A3 allelesJ Immunol199816112698569929862734
   PubMed Web of Science ®Google Scholar
• WolchokJDWeberJSHamidOIpilimumab efficacy and safety in patients with advanced melanoma: a retrospective analysis of HLA subtype from four trialsCancer Immun201010920957980
   PubMedGoogle Scholar
• RobertCThomasLBondarenkoIIpilimumab plus dacarbazine for previously untreated metastatic melanomaN Engl J Med2011364262517252621639810
   PubMed Web of Science ®Google Scholar
• WolchokJDHoosAO’DaySGuidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteriaClin Cancer Res200915237412742019934295
   PubMed Web of Science ®Google Scholar
• DowneySGKlapperJASmithFOPrognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockadeClin Cancer Res20071322 Pt 16681668817982122
   PubMed Web of Science ®Google Scholar
• YERVOY™ (ipilimumab) Immune-mediated Adverse Reaction Management GuideFDA-approved REMS Available at: http://www.yervoy.com/hcp/index.aspxAccessed November 23, 2011
   Google Scholar
• FlahertyKTFisherDENew strategies in metastatic melanoma: oncogene-defined taxonomy leads to therapeutic advancesClin Cancer Res201117154922492821670085
   PubMed Web of Science ®Google Scholar
• WoodmanSEDaviesMATargeting KIT in melanoma: a paradigm of molecular medicine and targeted therapeuticsBiochem Pharmacol201080556857420457136
   PubMed Web of Science ®Google Scholar
• FlahertyKTPuzanovIKimKBInhibition of Mutated, Activated BRAF in Metastatic MelanomaN Engl J Med2010363980981920818844
   PubMed Web of Science ®Google Scholar
• CarvajalRDAntonescuCRWolchokJDKIT as a therapeutic target in metastatic melanomaJAMA2011305222327233421642685
   PubMed Web of Science ®Google Scholar
• WoodmanSETrentJCStemke-HaleKActivity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlatesMol Cancer Ther2009882079208519671763
   PubMed Web of Science ®Google Scholar
• KlugerHMDudekAZMcCannCA phase 2 trial of dasatinib in advanced melanomaCancer2010117102202220821523734
   PubMed Web of Science ®Google Scholar
• SatzgerIKuttlerUVolkerBSchenckFKappAGutzmerRAnal mucosal melanoma with KIT-activating mutation and response to imatinib therapy – case report and review of the literatureDermatology20102201778119996579
   PubMed Web of Science ®Google Scholar
• AdjeiAACohenRBFranklinWPhase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in Patients With Advanced CancersJ Clin Oncol200826132139214618390968
   PubMed Web of Science ®Google Scholar